Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 11, 2013, Pages 1494-1505

  Collino, Massimo ^a   Rogazzo, Mara ^a   Pini, Alessandro ^b   Benetti, Elisa ^a   Rosa, Arianna Carolina ^a   Chiazza, Fausto ^a   Fantozzi, Roberto ^a   Bani, Daniele ^b   Masini, Emanuela ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acute kidney injury; Inflammation; Relaxin; Renal ischaemia reperfusion

Indexed keywords

RATTUS;

ANTIINFLAMMATORY AGENT; AUTACOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; NOS2 PROTEIN, RAT; NOS3 PROTEIN, RAT; PROTEIN KINASE B; RELAXIN;

ACUTE KIDNEY FAILURE; ANIMAL; ARTICLE; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN; INFLAMMATION; ISCHEMIA; KIDNEY; KIDNEY DISEASE; MALE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; RAT; RENAL ISCHAEMIA/REPERFUSION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; VASCULARIZATION; WISTAR RAT;

ACUTE KIDNEY INJURY; INFLAMMATION; RELAXIN; RENAL ISCHAEMIA/REPERFUSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INFLAMMATION MEDIATORS; ISCHEMIA; KIDNEY; KIDNEY DISEASES; MALE; MAP KINASE SIGNALING SYSTEM; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RELAXIN; REPERFUSION INJURY;

EID: 84891160261     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12120     Document Type: Article

References (55)

1. Bani D, Bigazzi M. Relaxin as a cardiovascular drug: a promise kept. Curr Drug Saf. 2011; 6: 324-8.
2. Masini E, Bani D, Bello MG, et al. Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology. 1997; 138: 4713-20.
3. Perna AM, Masini E, Nistri S, et al. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 2005; 19: 1525-7.
4. Masini E, Cuzzocrea S, Mazzon E, et al. Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion. Br J Pharmacol. 2006; 148: 1124-32.
5. Alexiou K, Matschke K, Westphal A, et al. Relaxin is a candidate drug for lung preservation: relaxin-induced protection of rat lungs from ischemia-reperfusion injury. J Heart Lung Transplant. 2010; 29: 454-60.
6. Wilson BC, Milne P, Saleh TM. Relaxin pretreatment decreases infarct size in male rats after middle cerebral artery occlusion. Ann N Y Acad Sci. 2005; 1041: 223-8.
7. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009; 373: 1429-39.
8. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013; 381: 29-39.
9. Lafayette RA, Hladunewich MA, Derby G, et al. Serum relaxin levels and kidney function in late pregnancy with or without preeclampsia. Clin Nephrol. 2011; 75: 226-32.
10. Unemori E, Sibai B, Teichman SL. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann N Y Acad Sci. 2009; 1160: 381-4.
11. Kong RC, Shilling PJ, Lobb DK, et al. Membrane receptors: structure and function of the relaxin family peptide receptors. Mol Cell Endocrinol. 2010; 320: 1-15.
12. Samuel CS, Hewitson TD. Relaxin in cardiovascular and renal disease. Kidney Int. 2006; 69: 1498-502.
13. Hewitson TD, Samuel CS. Relaxin: an endogenous renoprotective factor? Ann N Y Acad Sci. 2009; 1160: 289-93.
14. Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest. 1999; 103: 525-33.
15. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012; 380: 756-66.
16. Collino M, Patel NS, Lawrence KM, et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005; 68: 529-36.
17. Collino M, Benetti E, Miglio G, et al. Peroxisome proliferator-activated receptor beta/delta agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic Biol Med. 2011; 50: 345-53.
18. Patel NS, Cuzzocrea S, Collino M, et al. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol. 2007; 562: 148-54.
19. Cossum PA, Dwyer KA, Roth M, et al. The disposition of a human relaxin (hRlx-2) in pregnant and nonpregnant rats. Pharm Res. 1992; 9: 419-24.
20. Chen SA, Perlman AJ, Spanski N, et al. The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration. Pharm Res. 1993; 10: 834-8.
21. Baccari MC, Nistri S, Vannucchi MG, et al. Reversal by relaxin of altered ileal spontaneous contractions in dystrophic (mdx) mice through a nitric oxide-mediated mechanism. Am J Physiol Regul Integr Comp Physiol. 2007; 293: R662-8.
22. Bazzi C, Petrini C, Rizza V, et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant. 2002; 17: 1890-6.
23. Aruoma OI, Halliwell B, Laughton MJ, et al. The mechanism of initiation of lipid peroxidation. Evidence against a requirement for an iron(II)-iron(III) complex. Biochem J. 1989; 258: 617-20.
24. Nishida S, Teramoto K, Kimoto-Kinoshita S, et al. Change of Cu, Zn-superoxide dismutase activity of guinea pig lung in experimental asthma. Free Radic Res. 2002; 36: 601-6.
25. Patel NS, Kerr-Peterson HL, Brines M, et al. Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med. 2012; 18: 719-27.
26. Samuel CS, Hewitson TD. Relaxin and the progression of kidney disease. Curr Opin Nephrol Hypertens. 2009; 18: 9-14.
27. Nistri S, Cinci L, Perna AM, et al. Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. Pharmacol Res. 2008; 57: 43-8.
28. Cosen-Binker LI, Binker MG, Cosen R, et al. Relaxin prevents the development of severe acute pancreatitis. World J Gastroenterol. 2006; 12: 1558-68.
29. Danielson LA, Conrad KP. Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats. J Appl Physiol. 2003; 95: 1509-14.
30. Smith MC, Danielson LA, Conrad KP, et al. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol. 2006; 17: 3192-7.
31. Brecht A, Bartsch C, Baumann G, et al. Relaxin inhibits early steps in vascular inflammation. Regul Pept. 2011; 166: 76-82.
32. Dschietzig T, Bartsch C, Stangl V, et al. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J. 2004; 18: 1536-8.
33. Nistri S, Chiappini L, Sassoli C, et al. Relaxin inhibits lipopolysaccharide-induced adhesion of neutrophils to coronary endothelial cells by a nitric oxide-mediated mechanism. FASEB J. 2003; 17: 2109-11.
34. Dschietzig T, Brecht A, Bartsch C, et al. Relaxin improves TNF-alpha-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling. Cardiovasc Res. 2012; 95: 97-107.
35. Boehnert MU, Armbruster FP, Hilbig H. Relaxin as a protective substance in preservation solutions for organ transplantation, as shown in an isolated perfused rat liver model. Transplant Proc. 2008; 40: 978-80.
36. Boehnert MU, Hilbig H, Armbruster FP. Relaxin as an additional protective substance in preserving and reperfusion solution for liver transplantation, shown in a model of isolated perfused rat liver. Ann N Y Acad Sci. 2005; 1041: 434-40.
37. Mookerjee I, Hewitson TD, Halls ML, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009; 23: 1219-29.
38. Samuel CS, Zhao C, Bond CP, et al. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int. 2004; 65: 2054-64.
39. Baccari MC, Bani D. Relaxin and nitric oxide signalling. Curr Protein Pept Sci. 2008; 9: 638-45.
40. Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(omega)-nitro-L-arginine methyl ester hypertensive rats. Hypertension. 2011; 58: 197-204.
41. Luque Contreras D, Vargas Robles H, Romo E, et al. The role of nitric oxide in the post-ischemic revascularization process. Pharmacol Ther. 2006; 112: 553-63.
42. Kwon O, Hong SM, Ramesh G. Diminished NO generation by injured endothelium and loss of macula densa nNOS may contribute to sustained acute kidney injury after ischemia-reperfusion. Am J Physiol Renal Physiol. 2009; 296: F25-33.
43. Lopez-Neblina F, Paez AJ, Toledo AH, et al. Role of nitric oxide in ischemia/reperfusion of the rat kidney. Circ Shock. 1994; 44: 91-5.
44. Masini E, Nistri S, Vannacci A, et al. Relaxin inhibits the activation of human neutrophils: involvement of the nitric oxide pathway. Endocrinology. 2004; 145: 1106-12.
45. Bani D, Nistri S, Cinci L, et al. A novel, simple bioactivity assay for relaxin based on inhibition of platelet aggregation. Regul Pept. 2007; 144: 10-6.
46. McGuane JT, Debrah JE, Sautina L, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology. 2011; 152: 2786-96.
47. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296: 1655-7.
48. El Eter EA, Aldrees A. Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury. Shock. 2012; 37: 639-44.
49. Jang HS, Kim J, Kim KY, et al. Previous ischemia and reperfusion injury results in resistance of the kidney against subsequent ischemia and reperfusion insult in mice; a role for the Akt signal pathway. Nephrol Dial Transplant. 2012; 27: 3762-70.
50. Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995; 270: 1326-31.
51. Hung CC, Ichimura T, Stevens JL, et al. Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation. J Biol Chem. 2003; 278: 29317-26.
52. Chen M, Bao W, Aizman R, et al. Activation of extracellular signal-regulated kinase mediates apoptosis induced by uropathogenic Escherichia coli toxins via nitric oxide synthase: protective role of heme oxygenase-1. J Infect Dis. 2004; 190: 127-35.
53. Mendez N, Abarzua-Catalan L, Vilches N, et al. Timed maternal melatonin treatment reverses circadian disruption of the fetal adrenal clock imposed by exposure to constant light. PLoS ONE. 2012; 7: e42713.
54. Doi M, Shichiri M, Katsuyama K, et al. Cytokine-activated p42/p44 MAP kinase is involved in inducible nitric oxide synthase gene expression independent from NF-kappaB activation in vascular smooth muscle cells. Hypertens Res. 2000; 23: 659-67.
55. Sumi D, Ignarro LJ. Regulation of inducible nitric oxide synthase expression in advanced glycation end product-stimulated raw 264.7 cells: the role of heme oxygenase-1 and endogenous nitric oxide. Diabetes. 2004; 53: 1841-50.